We design it from day one, revolutionizing how protein therapeutics are developed. At Galux, we
develope a pioneering protein therapeutics design platform, GaluxDesign, that uniquely integrates
artificial intelligence and physical principles. We bring your imagined proteins to life.
Our platform
GaluxDesign: Integrating physics into AI
Our proprietary AI platform is trained to design proteins from first principles, resulting in
its modality-agnostic nature.
Its unprecedented accuracy has been demonstrated through the de novo design of antibodies, one of
the most challenging protein classes to design.
Latest stories from Galux
news
June 11, 2025
Galux and HanAll Biopharma Initiate Strategic Collaboration to Develop AI-Designed Antibody Therapeutics for Cancer
Read More
interview
May 26, 2025
Pioneering Precision: How South Korea's Galux is Redefining Antibody Discovery with AI
View Article
interview
March 20, 2025
Korean AI firm Galux develops six novel therapeutic antibodies using innovative design methods
View Article
Join forces with Galux to lead the next wave of drug innovation. Together, we push boundaries
and redefine what's possible in medicine.
Join our journey
Together, we push boundaries and shape the future of drug design.